EUVIMEDEUVIMED entdecken
Fallbericht

Telitacicept combined with glucocorticoids in adult-onset IgA vasculitis nephritis: A case report

Shunian Guo, Meng He, Hanyu Meng, Shu Rong

Clinical Nephrology · 2026

DOI: 10.5414/cn111984 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Nephrology, 2026. Verfasst von Shunian Guo und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Glucocorticoids, Prednisone, Glomerulonephritis, IGA, Recombinant Fusion Proteins.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: IgA vasculitis with nephritis (IgAVN), a severe renal manifestation of IgA vasculitis, is rare in adults and associated with high morbidity. Current therapies are suboptimal, highlighting the need for novel approaches. This case study evaluates telitacicept, a dual BAFF/APRIL inhibitor, in a high-risk adult IgAVN patient. MATERIALS AND METHODS: A 45-year-old male with biopsy-confirmed IgAVN, progressive renal impairment (estimated glomerular filtration rate (eGFR): 44 mL/min/1.73m2), and significant proteinuria (1.08 g/day) was treated with weekly subcutaneous telitacicept (160 mg) and oral prednisone. Clinical outcomes were assessed over 6 months. RESULTS: After 6 months, the patient showed rapid and sustained improvement: proteinuria decreased by 78.7% (from 1.08 to 0.23 g/day), and renal function stabilized (serum creatinine: 90.9 μmol/L; eGFR preserved). Prednisone was tapered and discontinued without relapse, demonstrating telitacicept's steroid-sparing effect. No treatment-related adverse events occurred. CONCLUSION: Telitacicept appeared to reduced proteinuria, stabilized renal function, and allowed corticosteroid withdrawal in refractory IgAVN. These findings suggest dual BAFF/APRIL inhibition as a promising strategy for IgA-mediated diseases, warranting further studies to confirm its role in IgAVN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucocorticoidsPrednisoneGlomerulonephritis, IGARecombinant Fusion ProteinsVasculitisHumansMaleMiddle AgedDrug Therapy, CombinationTreatment OutcomeProteinuriaB-Cell Activating FactorGlomerular Filtration RateKidney

Substanzen

GlucocorticoidsPrednisoneRecombinant Fusion ProteinsB-Cell Activating Factortelitacicept

Zitieren

APA

Guo, S., He, M., Meng, H., & Rong, S. (2026). Telitacicept combined with glucocorticoids in adult-onset IgA vasculitis nephritis: A case report. Clinical Nephrology. https://doi.org/10.5414/cn111984

Vancouver

Guo S, He M, Meng H, Rong S. Telitacicept combined with glucocorticoids in adult-onset IgA vasculitis nephritis: A case report. Clinical Nephrology. 2026. doi:10.5414/cn111984

BibTeX
@article{Guo2026,
  author = {Guo, Shunian and He, Meng and Meng, Hanyu and Rong, Shu},
  title = {Telitacicept combined with glucocorticoids in adult-onset IgA vasculitis nephritis: A case report},
  journal = {Clinical Nephrology},
  year = {2026},
  doi = {10.5414/cn111984}
}
Kostenlos starten →